Japan Oncology Market Outlook to 2033 - Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests and Others

Description

List of Tables

GlobalData's "Japan Oncology Market Outlook to 2033" is a comprehensive databook report, covering key market data on the Japan Oncology market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments - Colorectal Cancer Screening Tests, EGFR Tests, KRAS Tests, HER2 Tests, BRCA Tests, ALK Tests, BRAF Tests, BCR-ABL Tests and PD-L1 Tests

The Japan Oncology Market report provides key information and data on -

Annualized market revenues (USD), volume (units) and average prices (USD) data for each of the market segments. Data is provided from 2018 to 2033.
2024 company share data for Oncology Market.
Global corporate-level profiles of key companies operating within the Japan Oncology Market. Based on the availability of data for the particular category and country, information related to pipeline products, news and deals is also available in the report.

Scope

Japan Oncology is segmented as follows -

Colorectal Cancer Screening Tests
EGFR Tests
KRAS Tests
HER2 Tests
BRCA Tests
ALK Tests
BRAF Tests
BCR-ABL Tests
PD-L1 Tests

Reasons to Buy

The Japan Oncology Market report helps you to develop -

Business strategies by identifying the key market segments poised for strong growth in the future.
Market-entry and market expansion strategies.
Design competition strategies by identifying who-stands-where in the market.
Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
Understand the key distribution channels and what's the most preferred mode of product distribution - Identify, understand and capitalize.

Product Code: GDME25619CCDB

1 Table of Contents

1.1 List of Tables
1.2 List of Figures

2 Introduction

2.1 What Is This Report About?
2.2 Oncology Market Segmentation
2.3 Definitions of Markets Covered in the Report

3 Oncology Market, Japan

3.1 Oncology Market, Japan, Revenue ($m), 2018-2033
- 3.1.1 ALK Tests Market, Japan, Revenue ($m), by Segment, 2018-2033
- 3.1.2 BCR-ABL Tests Market, Japan, Revenue ($m), by Segment, 2018-2033
- 3.1.3 BRAF Tests Market, Japan, Revenue ($m), by Segment, 2018-2033
- 3.1.4 BRCA Tests Market, Japan, Revenue ($m), by Segment, 2018-2033
- 3.1.5 Colorectal Cancer Screening Tests Market, Japan, Revenue ($m), by Segment, 2018-2033
- 3.1.6 EGFR Tests Market, Japan, Revenue ($m), by Segment, 2018-2033
- 3.1.7 HER2 Tests Market, Japan, Revenue ($m), by Segment, 2018-2033
- 3.1.8 KRAS Tests Market, Japan, Revenue ($m), by Segment, 2018-2033
3.2 Oncology Market, Japan, Volume (Units), 2018-2033
- 3.2.1 ALK Tests Market, Japan, Volume (Units), by Segment, 2018-2033
- 3.2.2 BCR-ABL Tests Market, Japan, Volume (Units), by Segment, 2018-2033
- 3.2.3 BRAF Tests Market, Japan, Volume (Units), by Segment, 2018-2033
- 3.2.4 BRCA Tests Market, Japan, Volume (Units), by Segment, 2018-2033
- 3.2.5 Colorectal Cancer Screening Tests Market, Japan, Volume (Units), by Segment, 2018-2033
- 3.2.6 EGFR Tests Market, Japan, Volume (Units), by Segment, 2018-2033
- 3.2.7 HER2 Tests Market, Japan, Volume (Units), by Segment, 2018-2033
- 3.2.8 KRAS Tests Market, Japan, Volume (Units), by Segment, 2018-2033
3.3 Oncology Market, Japan, Average Price ($) , 2018-2033
3.4 Oncology Market, Japan, Company Share by Revenue ($m), 2024

4 Overview of Key Companies in Japan, Oncology Market

4.1 F. Hoffmann-La Roche Ltd
- 4.1.1 Company Overview
4.2 Agilent Technologies Inc
- 4.2.1 Company Overview
4.3 Abbott Laboratories
- 4.3.1 Company Overview
4.4 BioGenex Laboratories Inc
- 4.4.1 Company Overview
4.5 Danaher Corp
- 4.5.1 Company Overview
4.6 Amoy Diagnostics Co Ltd
- 4.6.1 Company Overview
4.7 Alfresa Pharma Corp
- 4.7.1 Company Overview
4.8 Qiagen NV
- 4.8.1 Company Overview
4.9 Eiken Chemical Co Ltd
- 4.9.1 Company Overview
4.10 SENTINEL CH SpA
- 4.10.1 Company Overview

5 Oncology Market Pipeline Products

6 Financial Deals Landscape

6.1 Debt Offerings
- 6.1.1 Astellas Pharma Prices USD545.6 Million in Public Offering of 0.87% Series 5 Unsecured Bonds Due 2029
- 6.1.2 Astellas Pharma Prices USD136.4 Million in Public Offering of 1.038% Series 6 Unsecured Bonds Due 2031
6.2 Venture Financing
- 6.2.1 The IT Lab Secures Venture Financing

7 Recent Developments

7.1 Corporate Communications
- 7.1.1 Apr 07, 2025: Ono Pharmaceutical Makes Changes of Board of Directors and Corporate Officers
- 7.1.2 Aug 23, 2024: Caris Life Sciences Announces Appointment of Dave Fredrickson to Board of Directors
7.2 Financial Announcements
- 7.2.1 May 08, 2025: Ono Pharmaceutical Reports Results for Fiscal Year Ended March 31, 2025
- 7.2.2 Nov 08, 2024: Human Metabolome Announces Consolidated Financial Results for the First Quarter of Fiscal Year Ending June 30, 2025
- 7.2.3 Aug 01, 2024: Astellas Pharma Announces Financial Results for Q1 FY2024
7.3 Government and Public Interest
- 7.3.1 May 08, 2025: Number of Patients Registered for Cancer Gene Panel Testing Under Health Insurance Coverage Reaches 100,000
7.4 Other Significant Developments
- 7.4.1 Feb 21, 2025: The OhmX RAMP UP Grant Awarded to 15 Laboratories to Advance Genomic Research
7.5 Product News
- 7.5.1 Nov 07, 2024: Nec and Nec Bio Publish Foundational Work on T Cell Receptor Engineering Using Proprietary Generative AI at the Society for Immunotherapy of Cancer Annual Meeting
- 7.5.2 Nov 05, 2024: National Cancer Center, Premia, and Paradigm Launch Treatment Development Platform "LC-SCRUM-CD''
- 7.5.3 Sep 26, 2024: Takara Bio Europe Unveils New Large-Scale NGS Profiling System and Chemistries
- 7.5.4 Sep 24, 2024: Industry-Academia Collaboration Nationwide Cancer Genome Screening SCRUM-Japan Launches Fifth Project
- 7.5.5 Sep 20, 2024: Approval for Manufacturing and Marketing of "Hemcyte(R)," Japan's First Gene Panel Test for Hematopoietic Tumors
- 7.5.6 Sep 17, 2024: Liquid Biopsy Confirmed to Be Useful in Deciding on Adjuvant Therapy After Surgery for Colorectal Cancer Liver Metastases
- 7.5.7 Sep 17, 2024: Scrum-Japan Gozila Project: Large-Scale Study of Over 4,000 Cases Confirms Extension of Survival Time Through Personalized Cancer Medicine
- 7.5.8 Aug 01, 2024: Development of a Method to Predict Onset of Non-Alcoholic Fatty Liver Disease -Contributing to Preventive Healthcare for Lifestyle Diseases
- 7.5.9 Jul 08, 2024: Noninvasive Urine Test for Early Detection of Cervical Cancer Virus Proteins
7.6 Strategy And Business Planning
- 7.6.1 Apr 28, 2025: PredxBio and Hamamatsu Photonics Announce Strategic Partnership to Deliver Next-Generation Spatial Biology Solutions for Cancer Research and Therapeutic Development
- 7.6.2 Apr 15, 2025: BCAN Announces Partnerships With Ferring Pharmaceuticals and Astellas/Pfizer Alliance
- 7.6.3 Apr 14, 2025: JelloX Biotech Establishes US Research Base
- 7.6.4 Jul 01, 2024: NURA Health Screening Center Opens in Hanoi, Vietnam

8 Appendix

8.1 Research Methodology
- 8.1.1 Coverage
- 8.1.2 Secondary Research
- 8.1.3 Primary Research
- 8.1.4 Market Modeling and Forecasting
- 8.1.5 Company Share Analysis
- 8.1.6 Benchmarking
8.2 GlobalData Consulting
8.3 Contact Us
8.4 Disclaimer

Product Code: GDME25619CCDB

List of Table

List of Tables

Table 1: Oncology Market, Japan, Revenue ($m), USD Constant, 2018-2033
Table 2: ALK Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033
Table 3: BCR-ABL Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033
Table 4: BRAF Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033
Table 5: BRCA Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033
Table 6: Colorectal Cancer Screening Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033
Table 7: EGFR Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033
Table 8: HER2 Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033
Table 9: KRAS Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033
Table 10: Oncology Market, Japan, Volume (Units), 2018-2033
Table 11: ALK Tests Market, Japan, Volume (Units), 2018-2033
Table 12: BCR-ABL Tests Market, Japan, Volume (Units), 2018-2033
Table 13: BRAF Tests Market, Japan, Volume (Units), 2018-2033
Table 14: BRCA Tests Market, Japan, Volume (Units), 2018-2033
Table 15: Colorectal Cancer Screening Tests Market, Japan, Volume (Units), 2018-2033
Table 16: EGFR Tests Market, Japan, Volume (Units), 2018-2033
Table 17: HER2 Tests Market, Japan, Volume (Units), 2018-2033
Table 18: KRAS Tests Market, Japan, Volume (Units), 2018-2033
Table 19: Oncology Market, Japan, Average Price ($), 2018-2033
Table 20: Oncology Market, Japan, Company Share by Revenue ($m), 2024
Table 21: Oncology Market Pipeline Products
Table 22: Astellas Pharma Prices USD545.6 Million in Public Offering of 0.87% Series 5 Unsecured Bonds Due 2029
Table 23: Astellas Pharma Prices USD136.4 Million in Public Offering of 1.038% Series 6 Unsecured Bonds Due 2031
Table 24: The IT Lab Secures Venture Financing
Table 25: Total Number of Primary Research Participants, In Vitro Diagnostics Market, by Country

List of Figure

List of Figures

Figure 1: Oncology Market, Japan, Revenue ($m), USD Constant, 2018-2033
Figure 2: ALK Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033
Figure 3: BCR-ABL Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033
Figure 4: BRAF Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033
Figure 5: BRCA Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033
Figure 6: Colorectal Cancer Screening Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033
Figure 7: EGFR Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033
Figure 8: HER2 Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033
Figure 9: KRAS Tests Market, Japan, Revenue ($m), USD Constant, 2018-2033
Figure 10: Oncology Market, Japan, Volume (Units), 2018-2033
Figure 11: ALK Tests Market, Japan, Volume (Units), 2018-2033
Figure 12: BCR-ABL Tests Market, Japan, Volume (Units), 2018-2033
Figure 13: BRAF Tests Market, Japan, Volume (Units), 2018-2033
Figure 14: BRCA Tests Market, Japan, Volume (Units), 2018-2033
Figure 15: Colorectal Cancer Screening Tests Market, Japan, Volume (Units), 2018-2033
Figure 16: EGFR Tests Market, Japan, Volume (Units), 2018-2033
Figure 17: HER2 Tests Market, Japan, Volume (Units), 2018-2033
Figure 18: KRAS Tests Market, Japan, Volume (Units), 2018-2033
Figure 19: Oncology Market, Japan, Company Share (%), 2024